Acelyrin (NASDAQ:SLRN) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Acelyrin (SLRN) operate in?

Acelyrin is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Acelyrin Stock (NASDAQ: SLRN) stock price, news, charts, stock research, profile.

Open	$4.66
Close	-
Volume / Avg.	852.49K / 891.22K
Day Range	4.61 - 5.02
52 Wk Range	3.67 - 29.88
Market Cap	$494.64M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	66
Short Interest	8.06%
Days to Cover	11.44

Recent News

Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Avi Kapoor

Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients

Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half of 2024.

Vandana Singh

Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study

Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high statistical significance. Long-term data in hidradenitis suppurativa show sustained clinical improvements, with HiSCR75 and HiSCR100 achievements. Phase 3 trial results expected by end of 2024.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Mar

Apr

May

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.5

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

About Acelyrin Inc

Sector

Health Care

Industry

Biotechnology

Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Acelyrin (SLRN) stock?

You can purchase shares of Acelyrin (NASDAQ:SLRN) through any online brokerage.

View our list of the best stock brokerages

Who are Acelyrin (SLRN) competitors?

Other companies in Acelyrin’s space includes: KalVista Pharma (NASDAQ:KALV), Valneva (NASDAQ:VALN), Voyager Therapeutics (NASDAQ:VYGR), Replimune Group (NASDAQ:REPL) and Altimmune (NASDAQ:ALT).

What is the target price for Acelyrin (SLRN) stock?

There is no analysis for Acelyrin.

What is the forecast for Acelyrin (SLRN) stock?

Acelyrin has a consensus price target of $18.86.

Current stock price for Acelyrin (SLRN)?

The stock price for Acelyrin (NASDAQ: SLRN) is $4.995 last updated Today at July 9, 2024 at 3:35 PM EDT.

Does Acelyrin (SLRN) pay a dividend?

There are no upcoming dividends for Acelyrin.

When is Acelyrin (NASDAQ:SLRN) reporting earnings?

Acelyrin’s Q2 earnings are confirmed for Monday, August 12, 2024.

Is Acelyrin (SLRN) going to split?

There is no upcoming split for Acelyrin.

What sector and industry does Acelyrin (SLRN) operate in?

Acelyrin is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acelyrin

Acelyrin (SLRN) Forecast